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ABSTRACT: A graft copolymer of α-elastin with poly(lactic-co-glycolic)
acid (PLGA) has been synthesized and successfully employed to produce
nanoparticles. Exploiting the known biological activity of α-elastin to
promote the maintenance of smooth muscle cells (SMCs) contractile
phenotype and the antiproliferative eﬀect of glucocorticoids, the aim of
this research was to produce drug-loaded nanoparticles suitable for
potential treatment of restenosis. In particular, nanoparticles of α-elastin-
g-PLGA with a mean size of 200 nm have been produced and loaded
with dexamethasone dipropionate (10% w/w), chosen as a model drug
that inhibits proliferation of vascular SMCs. These nanoparticles are able
to prolong the drug release and show a pronounced sensibility to elastase.
Drug unloaded nanoparticles stimulate the diﬀerentiation of human
umbilical artery smooth muscle cells (HUASMCs) toward the contractile
phenotype as demonstrated by immunoﬂuorescence, ﬂow cytoﬂuorimetric, and western blotting analyses. Finally, drug-loaded
nanoparticles eﬃciently reduce viability of HUASMCs as evidenced by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethox-
yphenyl)-2- (4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay.
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■ INTRODUCTION
Vascular healing is a complex physiological process essential for
maintaining vessel integrity and functionality. A dysfunction of
this process can produce an intimal hyperplasia because of an
abnormal migration and proliferation of vascular smooth
muscle cells (VSMCs).1 This hyperplasia can produce a
phenomenon known as restenosis, that leads to the vessel
obstruction where a tissue engineered vascular graft (TEVG) or
a stent has been implanted. Thus, the inhibition of this
hyperplasia is important to prolong patency of the implanted
TEGV or stent functionality. At this aim, the speciﬁc target of
therapeutic treatment is the key event of the hyperplasia, i.e.,
the proliferation of VSMCs. Indeed, VSMCs can assume both a
proliferative and contractile phenotype;2 in the ﬁrst case, cells
can rapidly proliferate and produce an extracellular matrix,
while the change into a contractile phenotype would allow a
better performance of TEGV or stent, thus reducing the risk of
restenosis. Several drugs, growth factors, or extracellular matrix
stimulating factors are potentially able to control the diﬀer-
entiation of VSMCs inhibiting the proliferative phenotype, and
some of these agents are currently in therapeutic use.3,4 In
particular, several antiinﬂammatory drugs are employed to
reduce proliferation of VSMCs after a reconstructive surgery or
they are loaded into stents to prevent restenosis.5,6 However,
the administration or loading of these drugs into stents without
an appropriate carrier able to prolong their release makes such
treatments often unsuccessful.7,8
Elastin is known to maintain a contractile phenotype of
VSMCs,9,10 inhibiting their migration and proliferation.1 It has
a morphogenetic role on diﬀerentiaton of SMC, acting via a G-
protein-coupled signaling pathway,1 and it has demonstrated a
reduction of restenosis after its administration in a pig model.
Dexamethasone dipropionate inhibits proliferation of
VSMCs,11 blocking cell cycle progression late in the G1
phase, and it has already been employed to treat restenosis in
stenting3 both as free drug and loaded into polymeric
nanoparticles.12
It is evident that, even if through a diﬀerent mechanism, both
elastin and dexamethasone are potentially employable to reduce
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restenosis and then if administered together they could have an
interesting synergetic eﬀect allowing to act both on SMC
phenotype and directly on diﬀerentiated cells, inhibiting their
proliferation. For this reason, in this work, we have prepared
new nanoparticles based on an α-elastin grafted to a
biocompatible and biodegradable polyester, such as polylactic-
co-glycolic acid (PLGA), loaded with dexamethasone dipropi-
onate. Physicochemical and biological properties of these
nanoparticles have been evaluated, as well as their ability to
prolong drug release.
■ EXPERIMENTAL SECTION
Materials and Methods. Poly(lactic-co-glycolic) acid
(PLGA) Resomer RG 502 H with an inherent viscosity of
0.19 dL/g, Mw 3000 Da, was purchased by Boehringer−
Ingelheim (Milan, Italy). Bis(4-nitrophenyl)carbonate (4-
NPBC), 4-nitrophenyl chloroformate, elastin from bovine
neck ligament, pancreatic elastase from porcine pancreas,
pyridine, dexamethasone dipropionate (DEX), Dulbecco’s
phosphate buﬀered solution (DPBS), and Dulbecco’s modiﬁed
eagle medium (DMEM) were purchased from Sigma-Aldrich
(Milan, Italy). D-(+) trealose dihydrate and ethylenediamine
(EDA) were purchased from Fluka (Milan, Italy).
FT-IR spectra were performed by using a Perkin-Elmer 1720
spectrophotometer in the range 4000−400 cm−1. 1H NMR
spectra were obtained with a Bruker AC-300 instrument. High
performance liquid chromatography (HPLC) analysis has been
performed by using an Agilent 1100 series with an Agilent
injector 7725i and a UV detector Agilent 1100 equipped with a
column Symmetry (Waters, C18, 5 μm 150 × 4.6 mm),
employing as an eluent acetate buﬀer 1 mM pH 4.8/acetonitrile
in a ratio 25/75 v/v, with a ﬂow of 0.8 mL/min and a λ value of
243 nm. Size exclusion chromatography (SEC) analysis was
performed using a multidetector SEC system equipped with a
Water 600 pump and a Water 410 Refractive Index Detector
with Phenogel column employing as an eluent LiCl 0.05 M in
DMF mixed with DMSO in a ratio 9:1 and a ﬂow of 0.6 mL/
min. Dynamic light scattering measurements were performed
by using a Zetasizer Nano ZS instrument (Malvern Instrument,
Germany). Transmission electron microscopy (TEM) images
were recorded by using a JEOL JEM-2100 instrument.
α-Elastin Extraction from Bovine Elastin. The extraction
of α-elastin from elastin of bovine neck was performed
following the procedure of Partridge et al.13 Brieﬂy, 1 g of
bovine elastin was suspended in 0.25 M oxalic acid solution and
hydrolyzed by sequential cycles of heating for 1 h in a water
boiling bath. The supernatant was collected by centrifugation,
and the precipitated solid was treated until complete hydrolysis.
The collected soluble fractions were dialyzed against water
using a dialysis membrane tube of 3500 Da and then freeze-
dried. The obtained powder was dissolved in acetic acid
solution 0.01 M containing NaCl 0.1 M (1 g of hydrolyzed
elastin in 10 mL of acidic solution) and heated at 50 °C for 15
min to obtain the α-elastin coacervation. The coacervate was
collected by centrifugation. The procedure was repeated until
complete precipitation of α-elastin. The α-elastin was ﬁnally
dissolved in acetic acid solution 0.1 M and dialyzed against
acetic acid solution using a dialysis membrane of 3500 Da at 4
°C for 1 day. Finally, the solution was freeze-dried and the α-
elastin was stored as a powder.
Synthesis of PLGA-Ethylenediamine (PLGA-EDA) De-
rivative. The synthesis of the PLGA-EDA derivative was
performed similarly to the functionalization of polycaprolac-
tone, as described by Choi and colleagues,14 with some
modiﬁcations. In particular, pyridine and 4-nitrophenyl
chloroformate have been added to a solution of PLGA in
dichloromethane 10% w/v in a molar excess of 1.2 and 3,
respectively. After 3 h at room temperature, the PLGA-
nitrophenyl derivative was precipitated into an excess of diethyl
ether, washed with ethanol, and dried under a vacuum (yield
100% w/w). The 1H NMR spectrum (CDCl3) showed the
following peaks: δ 1.59 (2d, 3H, −CO−CH(CH3)−O− of
PLGA), δ 4.86 (s, 2H, −CO−CH2−O− of PLGA), δ 5.22 (2d,
1H, −CO−CH(CH3)−O− of PLGA), δ 8.03−δ 8.87 (m, 4H,
p-nitrophenyl moiety).
Ethylenediamine (EDA) was added to the solution of PLGA-
nitrophenyl derivative (4% w/v) in dichloromethane, in a molar
ratio EDA/PLGA-nitrophenyl derivative equal to 2. After 3 h at
room temperature, the PLGA-EDA derivative was puriﬁed by
precipitation into diethyl ether; then, the product was dissolved
in acetone and precipitated into few volumes of NaCl saturated
solution (100 μL per gram of product). Finally, the product was
washed with a mixture ethanol/water 8:2 and then with
ethanol. The puriﬁcation of the PLGA-EDA derivative was
conﬁrmed by HPLC analysis. The 1H NMR spectrum (in
CDCl3) of PLGA-EDA derivative showed peaks at δ 1.59 (2d,
3H, −CO−CH(CH3)−O− of PLGA), δ 2.2 (m, 2 H, −CO−
NH−CH2−CH2−NH2 of EDA), δ 4.85 (s, 2H, −CO−CH2−
O− of PLGA), and δ 5.21 (2d, 1H, −CO−CH(CH3)−O− of
PLGA).
Synthesis of α-Elastin-g-PLGA Copolymers. Three
diﬀerent weight ratios of PLGA-EDA/α-elastin were employed
equal to 2, 4, and 6 (samples a, b, and c, respectively), and a
two-step reaction was performed in the following way.
Step 1: α-elastin (3.3% w/v in anhydrous DMSO) was
activated by employing 4-NPBC (weight ratio α-elastin/4-
NPBC equal to 6) for 3 h at 40 °C.15 Step 2: the solution of
activated α-elastin was added to PLGA-EDA solution (40% w/v
in anhydrous DMSO) in an amount corresponding to the
chosen weight ratio reported above. The reaction solution was
maintained at 40 °C for 24 h. Then, it was precipitated in
ethanol and the product was washed with acetone. The α-
elastin-g-PLGA was obtained with a yield of 80% w/w.
Puriﬁcation from the unreacted PLGA-EDA was conﬁrmed
by SEC analysis.
The FT-IR spectrum (in KBr) showed the main following
peaks: a broad band centered at 3450 cm−1 (νas OH + νas NH
of elastin), shoulder at 1780 cm−1 (νas COO of PLGA), 1655
and 1533 cm−1 (amides of α-elastin). The 1H NMR spectrum
(in DMF-d6) showed the following peaks: δ 0.77 and 1.22 (s,
9H, −NH−CH(CH3)COO− of alanine and −NH−CH−
(CH(CH3)2)−COO− of valine of α-elastin, respectively), δ
1.59 (2d, 3H, −CO−CH(CH3)−O− PLGA), δ 4.9 (s, 2H,
−CO−CH2−O− PLGA), and δ 5.25 (2d, 1H, −CO−
CH(CH3)−O− PLGA). The amount of PLGA grafted to α-
elastin was calculated comparing the area of the peaks
attributable to protons of −CO−CH2−O− and CO−
CH(CH3)−O− of PLGA (δ 4.9 and 5.25, respectively) with
the area of peaks attributable to methyl groups of valine and
alanine residues of α-elastin.
In addition, to evaluate the activation eﬃciency of α-elastin
with 4-NPBC in the ﬁrst step of the reaction, the 4-NPBC
activated α-elastin was precipitated in acetone and washed
several times with the same solvent. The molar amount of 4-
NPBC in α-elastin was determined by colorimetric assay after
treatment with NaOH 0.1 N. In particular, 5 mg of activated α-
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elastin was dissolved in NaOH 0.1 N and the absorbance was
read at 405 nm. A calibration curve of 4-NPBC in NaOH 0.1 N
was used for the quantitative determination of 4-NPBC
released from activated α-elastin. The molar percentage of α-
elastin activated by 4-NPBC was determined considering a
mean molecular weight of 105 Da for aminoacids in α-elastin as
reported elsewhere.16
α-Elastin-g-PLGA Nanoparticles: Preparation, Charac-
terization, and in Vitro Drug Release Studies. α-Elastin-g-
PLGA copolymer (sample a) was dispersed in DMSO with a
concentration ranging from 2.5 to 15 mg/mL. To prepare drug-
loaded nanoparticles, dexamethasone dipropionate was added
in an amount corresponding to 0.5-fold the weight of
copolymer. Dispersions were added drop by drop with a
microsyringe into an excess of bidistilled water (ratio DMSO
solution:bidistilled water equal to 1:15) under stirring at 9500
rpm by using a Ultraturrax apparatus. The obtained dispersion
was dialyzed against water for 3 days by using a Spectrapor
dialysis tube (12000−14000 Da). Finally, a dialyzed dispersion
was ﬁltered through a 5 μm cellulose acetate ﬁlter and freeze-
dried. Size and zeta potential values of empty and drug-loaded
nanoparticles were evaluated with a Zetasizer Nano ZS
instrument in diﬀerent media such as bidistilled water, DPBS
pH 7.4, and DMEM. The size and shape of nanoparticles were
also evaluated by TEM analysis. In particular, samples were
prepared by dispersing α-elastin-g-PLGA nanoparticles in
bidistilled water (1 mg/mL) in a copper grid and drying at
room temperature.
The amount of dexamethasone dipropionate loaded into
nanoparticles was evaluated by HPLC analysis. In particular, 0.1
mL of a dispersion of drug-loaded nanoparticles in DMSO (10
mg/mL) was diluted with acetonitrile (1 mL) and then the
obtained dispersion was ﬁltered (0.45 μm) before HPLC
analysis. To evaluate the release of dexamethasone dipropio-
nate, drug-loaded α-elastin-g-PLGA nanoparticles were dis-
persed in DPBS pH 7.4 (1 mL) with or without the presence of
elastase (1 U/mL) and sealed into a dialysis bag (14 000 Da)
against 9 mL of DPBS pH 7.4, under stirring and at 37 °C. At
scheduled times, 1 mL of external medium was collected and
used for drug quantiﬁcation by HPLC and then replaced by
fresh DPBS pH 7.4. After 1 and 10 days, nanoparticle
dispersion was recovered from the dialysis bag and freeze-
dried to determine the amount of dexamethasone dipropionate
remaining in the nanoparticles. Each experiment was performed
in triplicate.
In Vitro Culture of Human Umbilical Artery Smooth
Muscle Cells. Human umbilical artery smooth muscle cells
(HUASMCs) were purchased from European Collection of
Cell Cultures (ECACC). Cells were cultured in a basal growth
medium (Smooth Muscle Cell Growth Medium from Cell
Application, Inc. Cat No 311K-500) supplemented with 3%
growth factors, 10% fetal bovine serum (FBS; Euroclone
Celbio), 1% antibiotic, and 1% glutamine (Euroclone Celbio).
Cells were cultured in ﬂasks (75 cm2; Corning), and when
conﬂuent, they were detached using tripsin-EDTA solution 1×
(Sigma) and seeded on a culture multiwell plate (Corning) or
on a coverslip, to perform diﬀerent analyses.
Morphological Analysis. HUASMCs were seeded at low
density (5000 cells/well) on a sterile coverslip in a culture 12
well-plate. After 24 h, cells were incubated in a basal growth
medium at 37 °C alone (growth control) or in the presence of
30 μg/mL α-elastin-g-PLGA nanoparticles. As diﬀerentiated
control, cells were incubated with a diﬀerentiating growth
medium (Smooth Muscle Cell Diﬀerentiation Medium from
Euroclone Celbio). This medium is speciﬁcally designed to
promote diﬀerentiation of smooth muscle cells in culture and to
maintain their mature contractile phenotype. The culture
medium was changed every 2 days, and a new dose of
nanoparticles (30 μg/mL) was added each time. After 4 days of
incubation, cells were ﬁxed on a coverslip using formaldehyde
3.7% for 15 min and permeabilized with Triton 0.1%; then, the
actin cytoskeleton was stained with phalloidin-FITC (1:500)
for 1 h at 37 °C. Cells were thoroughly washed in phosphate
buﬀer saline, and their nuclei were stained with propidium
iodide (1:1000) for 1 h at 37 °C.17 Cell proliferation was
evaluated by quantiﬁcation of phalloidin-FITC actin ﬁbers/ﬁeld
related to the mean cell area for each sample in the diﬀerent
culture conditions (10 random ﬁelds for each sample), using
the Image J64 software. Data were expressed as arbitrary units
(A.U.). Morphological analysis was performed by confocal
microscopy observation (Olympus 1 × 70 with Melles Griot
laser system).
Flow Cytoﬂuorimetric Analysis. HUASMCs were seeded
at high density (50 000 cells/well) in a culture 6 well-plate, and
after 24 h, they were incubated as previously described. After 4
days of incubation, cells were detached using Tripsin-EDTA
solution 1× and counted using the Thoma chamber, and then,
800 000 cells/sample were centrifuged at 1000 rpm for 10 min.
HUASMCs were treated with 500 μL of propidium iodide
solution (50 μg/mL) and incubated for 45 min under dark
conditions. The cell cycle was analyzed by FACS (BD
FACSDiva version 6.1.2). Each experiment was performed in
triplicate.
Western Blotting Analysis. HUASMCs were seeded at
high density (50 000 cells/well) in a culture 6 well-plate, and
after 24 h, they were incubated as previously described. After 4
days of incubation, cells were mechanically detached and
centrifuged at 1000 rpm for 10 min. The extracts were obtained
treating the pelleted cells with 70 μL of 1% Triton X-100
solution for 10 min at room temperature and then centrifuged
at 10 000 rpm for 10 min. The amount of proteins in the cell
extracts was quantiﬁed by the Bradford microassay method
(Bio-Rad, Segrate, Milan, Italy), using bovine serum albumin
(Sigma-Aldrich) as a standard. A 5 μg portion of each extract
was analyzed by SDS-PAGE and blotted on nitrocellulose. By
Western blotting analysis, the amount of α smooth muscle actin
for each sample was evaluated and quantiﬁed by densitometric
analysis with Image J64 software. Each experiment was
performed in triplicate.
Cell Viability Assay. HUASMCs were seeded at high
density (50 000 cells/well) on a sterile coverslip in a culture 24
well-plate. After 24 h, cells were incubated in a basal growth
medium for 48 h at 37 °C alone (control) or in the presence of
drug-loaded α-elastin-g-PLGA nanoparticles dispersed in
DMEM. As a comparison, cells were also incubated in a basal
growth medium in the presence of free drug dissolved in
DMSO. The concentration of free dexamethasone was 50 μg/
mL, and the amount of drug-loaded α-elastin-g-PLGA nano-
particles was 450 μg/mL (this value corresponds to a drug
concentration of 50 μg/mL). A blank of α-elastin-g-PLGA
nanoparticles without drug was also assayed by using a
concentration of 450 μg/mL. The viability of each sample
was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-tetrazolium,
inner salt (MTS) assay (Cell Counting Kit; Sigma). After 3
h, the absorbance of each sample was read at 490 nm in a
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GloMax-Multi Detection System (Promega). Each experiment
was performed in triplicate.
■ RESULTS AND DISCUSSION
Despite a wide application of native elastin in regenerative
medicine,18 its use for the production of nanoparticles for drug
release is limited by its poor solubility in several media. The
acidic hydrolysis of desmosine bridges in native elastin allows
the production of α-elastin soluble both in aqueous and organic
media.19 Recently, α-elastin has been employed for the
production of nanoparticles by high temperature coacervation
and cross-linking through γ irradiation.20 On the other hand, it
is well-known that nanocarriers are useful to improve
bioavailability of poorly water-soluble drugs;21 therefore, the
grafting of a hydrophobic moiety on the α-elastin chain could
be exploited to produce appropriate nanoparticles able to
entrap lipophilic drugs, such as dexamethasone dipropionate.
For this reason, in this work, PLGA with a Mw value of about
3000 Da has been chosen as a hydrophobic moiety and grafted
to α-elastin through a simple and reproducible chemistry, even
if α-elastin has few reactive groups (more than 80% of
aminoacids are alanin, valine, proline, and glycine).16
4-NPBC has been chosen as an activator of hydroxyl groups
in α-elastin (see Figure 1), and about 1.8 mol % of total
aminoacids have been activated as evaluated by UV analysis
(see the Experimental Section). This amount corresponds to
about 50 mol % of hydroxyl groups containing aminoacids. At
the same time, the reaction between PLGA activated by 4-
nitrophenyl chloroformate and ethylenediamine (EDA) has
been performed to obtain PLGA-EDA derivative. Then, the
reaction between PLGA-EDA and the activated α-elastin has
been performed in anhydrous DMSO, by using three diﬀerent
Figure 1. Schematic representation of activation of α-elastin with 4-NPBC and grafting of PLGA-EDA to obtain α-elastin-g-PLGA copolymer.
Table 1. Grafting Degree in PLGA (GDPLGA, mol %) for α-
Elastin-g-PLGA Copolymers Obtained by Using Diﬀerent
Weight Ratios between PLGA-EDA and α-Elastin (Mean
Value ± Standard Deviation, n = 3)
weight ratio PLGA-EDA/α-elastin GDPLGA (mol %)
2 (sample a) 1.28 ± 0.04
4 (sample b) 1.38 ± 0.02
6 (sample c) 1.32 ± 0.02
Table 2. Values of Drug Loading (% w/w) and Loading
Eﬃcacy (% w/w) in α-Elastin-g-PLGA Nanoparticles
Prepared by Using Diﬀerent Concentrations of Sample a







2.5 1.0 ± 0.2 3 ± 0.1
5 3.0 ± 0.3 9 ± 0.3
7.5 10.0 ± 0.2 30 ± 0.2
15 13.0 ± 0.1 39 ± 0.2
Table 3. Values of Mean Diameter (MD), Polydispersity
Index (PDI), and Zeta Potential (Pz) of Unloaded and Drug-
Loaded α-Elastin-g-PLGA Nanoparticles in Bidistilled





drug unloaded bidistilled water 198.8 0.356 −20.3
DPBS pH 7.4 204.6 0.264 −9.9
DMEM pH 7.4 184.8 0.307 −9.2
drug loaded bidistilled water 224.9 0.390 −22.8
DPBS pH 7.4 220.7 0.322 −10.8
DMEM pH 7.4 221.0 0.382 −9.5
Molecular Pharmaceutics Article
dx.doi.org/10.1021/mp4004157 | Mol. Pharmaceutics 2013, 10, 4603−46104606
weight ratios of PLGA-EDA/α-elastin (2, 4, or 6) in order to
synthesize the corresponding α-elastin-g-PLGA copolymer
(sample a, b, or c) (see Figure 1).
1H NMR and FTIR analyses performed on each α-elastin-g-
PLGA copolymer have conﬁrmed the success of the grafting
procedure. Table 1 reports the amount of PLGA grafted to α-
elastin, calculated by 1H NMR analysis for all copolymers (see
the Experimental Section).
It is evident that the grafting degree in PLGA does not
change signiﬁcantly by increasing the weight ratio of PLGA-
EDA/α-elastin, and a mean value equal to about 1.3 mol % has
been obtained. This amount corresponds to the functionaliza-
tion of about 40% of total free hydroxyl groups in α-elastin, and
this means that the 80% of aminoacids activated with 4-NPBC
(that are 1.8 mol % as calculated by colorimetric assay)
eﬃciently reacted with PLGA-EDA, thus conﬁrming the
success of the grafting reaction of PLGA-EDA on the α-elastin
chain.
Figure 2. TEM pictures of drug unloaded α-elastin-g-PLGA nanoparticles obtained at 10k (left) and 25k (right).
Figure 3. In vitro release proﬁles of dexamethasone dipropionate from
α-elastin-g-PLGA nanoparticles in DPBS pH 7.4 at 37 °C. Experi-
ments were performed in the absence (◆) or in the presence (▲) of
elastase (1 U/mL).
Figure 4. (A) Morphological analysis: HUASMCs incubated in a basal growth medium alone (growth control) or in the presence of α-elastin-g-
PLGA nanoparticles, without drug. Cells incubated with diﬀerentiating growth medium have been used as a diﬀerentiated control. Cells were stained
with phalloidin-FITC (green) and propidium iodide (red) and observed by a confocal microscope. (B) % of cells (as amount of red ﬂuorescent
nuclei) for each culture condition. The analysis was carried out by Image J64 software.
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All α-elastin-g-PLGA copolymers were not soluble in water
but very soluble in DMSO; however, considering the similar
grafting degree in PLGA, only one copolymer (sample a) has
been chosen for the production of nanoparticles. In particular,
as reported in the Experimental Section, α-elastin-g-PLGA
nanoparticles have been prepared by the nanoprecipitation
technique using a copolymer (sample a) concentration ranging
from 2.5 to 15 mg/mL in DMSO and distilled water has been
used as a precipitating medium. Drug-loaded nanoparticles have
been prepared by dissolving dexamethasone dipropionate in
DMSO in an amount corresponding to 0.5-fold the weight of
copolymer.
As shown in Table 2, both drug loading and loading eﬃcacy
increase with copolymer concentration, reaching a value of 13
and 39% w/w, respectively, for a concentration of 15 mg/mL.
However, at this concentration, drug-loaded nanoparticles were
not dispersible in aqueous medium; on the contrary, nano-
particles obtained with a copolymer concentration of 7.5 mg/
mL give a ﬁne aqueous dispersion. For this reason, nano-
particles having a drug loading of 10% w/w and a loading
eﬃcacy of 30% w/w have been used for further character-
ization.
Table 3 reports the values of mean diameter and zeta
potential of these nanoparticles determined in diﬀerent media
by dynamic light scattering measurements.
For each sample, no signiﬁcant diﬀerence has been found by
changing the external medium. The presence of drug causes an
increase of about 10% in nanoparticle diameter, but it does not
aﬀect the value of the zeta potential, thus indicating that
dexamethasone dipropionate is above all entrapped inside the
nanoparticle and not on the surface. TEM analysis has
conﬁrmed dynamic light scattering data, showing nanoparticles
of about 200 nm with a narrow size distribution. Figure 2
reports, as an example, TEM images of drug unloaded
nanoparticles.
The release proﬁle reported in Figure 3 shows that, in the
absence of enzyme, a plateau is obtained after 8 h and only
about 40% of drug is released. The presence of elastase (1 U/
mL) causes a pronounced increase in the amount of released
drug that, after 4 h, is about 70% with respect to the total
amount. This result demonstrates that α-elastin even if grafted
to PLGA maintains its susceptibility toward elastase that is able
to hydrolyze its chains, thus allowing a faster drug release.
However, after 24 h, a signiﬁcant amount of drug remains still
entrapped into the nanoparticles, both in the absence and in the
presence of elastase. Unfortunately, after 24 h, dexamethasone
dipropionate released in DPBS pH 7.4 undergoes a signiﬁcant
hydrolysis, giving rise to dexamethasone monopropionate and
dexamethasone, thus making the analysis of release proﬁle for
longer times diﬃcult. However, in order to evaluate if α-elastin-
g-PLGA nanoparticles are able to prolong the drug release, after
10 days, nanoparticle dispersion was recovered from the dialysis
bag and freeze-dried to determine the amount of dexametha-
sone dipropionate remaining in the nanoparticles. This amount
resulted in being the 10% w/w for nanoparticles treated with
elastase and 25% w/w for nanoparticles in the absence of
elastase. The obtained result suggests that α-elastin-g-PLGA
nanoparticles are able to release in a prolonged way (for more
than 10 days) a poorly soluble drug, such as dexamethasone
dipropionate.
As reported in the Introduction, both elastin and dexa-
methasone have an inhibitory eﬀect on SMC proliferation, even
if with a diﬀerent mechanism. Therefore, with the aim of
diﬀerentiating between drug-loaded nanoparticles and non-
drug-loaded nanoparticles, diﬀerent biological assays have been
performed, i.e., (1) morphological, ﬂow cytoﬂuorimetric, and
Western blotting analyses to evaluate the role of α-elastin in α-
elastin-g-PLGA nanoparticles in the absence of drug and (2) a
MTS assay to evaluate the antiproliferative eﬀect of dexa-
methasone dipropionate loaded into α-elastin-g-PLGA nano-
particles in comparison with empty α-elastin-g-PLGA nano-
particles and free dexamethasone dipropionate.
Figure 5. Flow cytometric proﬁle of HUASMCs incubated in a basal
growth medium alone (growth control) or in the presence of α-elastin-
g-PLGA nanoparticles, without drug. Cells incubated with diﬀer-
entiating growth medium have been used as a diﬀerentiated control.
The histograms report the % of cells in each phase of the cell cycle.
Figure 6. Western blotting analysis for α SM actin expression from
HUASMCs incubated in a basal growth medium alone (growth
control, A) or in the presence of α-elastin-g-PLGA nanoparticles,
without drug (C). Cells incubated with diﬀerentiating growth medium
have been used as a diﬀerentiated control (B). The histograms report
the densitometric evaluation of each line, determined by Image J64
software. The values were expressed as % of α SM actin for each
sample.
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In particular, by morphological analysis, the potential of α-
elastin-g-PLGA nanoparticles to stimulate the diﬀerentiation
toward the contractile phenotype of HUASMCs during the in
vitro culture has been evaluated. Cells have been incubated with
basal growth medium alone (growth control) or in the presence
of α-elastin-g-PLGA nanoparticles. Cells incubated with
diﬀerentiating growth medium have been used as a diﬀer-
entiated control (see the Experimental Section). In agreement
with data reported in the literature, the morphological analysis
(Figure 4A) evidenced that cells treated with α-elastin-g-PLGA
nanoparticles show in their cytoplasm a highly organized
network of actin stress ﬁbers, a hallmark of mature contractile
vascular smooth muscle cells, like the diﬀerentiated control.
An image analysis has been performed using Image J64
software to evaluate the number of cells for each colture
condition. In particular, the % of red ﬂuorescent nuclei for each
sample was quantiﬁed and reported in Figure 4B. It is evident
that the % of HUASMCs decreases with the following order:
control cells (considered as 100% of proliferation) > cells
treated with nanoparticles (69%) > diﬀerentiated control
(38%). This result suggests that proliferation of cells treated
with α-elastin-g-PLGA nanoparticles (without drug) decreases
due to the gradual diﬀerentiation toward the contractile
phenotype.
To conﬁrm these data, ﬂow cytoﬂuorimetric analysis has also
been performed. As it is possible to observe in Figure 5, for
HUASMCs treated with α-elastin-g-PLGA nanoparticles (with-
out drug), like for diﬀerentiated control, the % of cells in phase
G0−G1 is greater than growth control, thus conﬁrming the
diﬀerentiation toward a contractile phenotype due to the
presence of α-elastin-g-PLGA nanoparticles.
Moreover, by a Western blotting analysis, the amount of α
smooth muscle actin (α SM actin) has been determined, with
this protein being a speciﬁc marker of SMC diﬀerentiation.22 As
shown in Figure 6, the % of α SM actin in cells treated both
with α-elastin-g-PLGA nanoparticles and with diﬀerentiating
growth medium is higher than growth control, thus conﬁrming
again that the presence of α-elastin-g-PLGA nanoparticles,
without drug, promotes the diﬀerentiation toward the
contractile phenotype.
However it is appropriate to relate the percentage of
expression of α SM actin with the mean area of the cells
cultured under diﬀerent conditions. Indeed, it is important to
specify that, for sample A (growth control) of Figure 6, the α
SM actin expression (basal level) is due to a high number of
cells present in the control. On the contrary, the α SM actin
expression for sample C (HUASMCs treated with α-elastin-g-
PLGA nanoparticles) is due to a lower number of cells (with a
greater mean area) having a diﬀerentiated contractile
phenotype.
Finally, a MTS assay has been performed to evaluate the
antiproliferative eﬀect of dexamethasone dipropionate loaded
into nanoparticles. HUAMCs incubated in basal growth
medium were used as a control, whereas α-elastin-g-PLGA
nanoparticles without drug were used as a blank. Results have
been compared with those obtained by using free dexametha-
sone dipropionate dissolved in DMSO.
As shown in Figure 7, viability of HUASMCs incubated for
48 h in the presence of α-elastin-g-PLGA nanoparticles without
drug (blank) is equal to that of cells treated with basal growth
medium alone. On the contrary, drug-loaded nanoparticles
cause a pronounced decrease in cell viability like free
dexamethasone dipropionate. The obtained results demonstrate
that, according to the diﬀerent action mechanism of α-elastin
and dexamethasone, as mentioned above, MTS assay allows
one to evaluate only the antiproliferative eﬀect of drug
entrapped into nanoparticles.
To sum up, biological assays diﬀerentiate between drug-
loaded and non-drug-loaded nanoparticles, thus demonstrating
the beneﬁt due to the combination of α-elastin-g-PLGA and
dexamethasone dipropionate for a potential treatment of
restenosis.
■ CONCLUSIONS
A simple and reproducible grafting reaction has been described
to obtain an α-elastin-g-PLGA copolymer employed for the
production of nanoparticles potentially useful to prevent
restenosis. In particular, nanoparticles with a mean diameter
of 200 nm have been produced and successfully employed to
entrap dexamethasone dipropionate, a known drug that inhibits
proliferation of vascular smooth muscle cells (VSMCs). Thanks
to the activity of α-elastin in regulating smooth muscle cell
phenotype, α-elastin-g-PLGA nanoparticles alone are able to
stimulate the diﬀerentiation of human umbilical artery smooth
muscle cells toward the contractile phenotype, as evidenced by
diﬀerent biological studies like immunoﬂuorescence, ﬂow
cytoﬂuorimetric, and western blotting analyses. Moreover,
drug-loaded nanoparticles exhibit in aqueous medium a good
antiproliferative eﬀect comparable to that of free drug dissolved
in organic medium. Therefore, α-elastin-g-PLGA nanoparticles
Figure 7. Viability of HUASMCs determined by MTS assay after their incubation with basal growth medium alone (control) or in the presence of α-
elastin-g-PLGA nanoparticles without drug (blank), drug-loaded α-elastin-g-PLGA nanoparticles (450 μg/mL), or free drug (DEX, 50 μg/mL). The
amount of drug-loaded α-elastin-g-PLGA nanoparticles (450 μg/mL) corresponds to a DEX concentration of 50 μg/mL.
Molecular Pharmaceutics Article
dx.doi.org/10.1021/mp4004157 | Mol. Pharmaceutics 2013, 10, 4603−46104609
show an intrinsic ability to promote the diﬀerentiation toward
the contractile phenotype combined with the antiproliferative
eﬀect of dexamethasone dipropionate. In addition, release
studies have shown that α-elastin-g-PLGA nanoparticles act as a
drug reservoir, thus allowing a prolonged release in aqueous
medium without the use of organic solvent. The obtained
results can be considered as positive preliminary data for a
further design of innovative devices for restenosis treatment.
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